Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

25.31 +0.39 (+1.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 Next >
These stocks are moving in today's session
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Arcutis Q3 2025 Earnings Call Transcript
Arcutis Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Top stock movements in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Earnings Scheduled For October 28, 2025
 
Via Benzinga
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Crude Oil Falls Over 2%; PayPal Shares Spike Higher
 
Via Benzinga
Here's Why This Biotherapeutics Company's Stock Surged Higher by 30% Today
Arcutis Biotherapeutics had an excellent update for investors and its future looks bright. 
Via The Motley Fool
Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise.
Arcutis Biotherapeutics smashed quarterly calls Tuesday and reported its first-ever positive net income. 
Via Investor's Business Daily
Traders are paying attention to the gapping stocks in Tuesday's session.
Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Reports Strong Q3 2025 Earnings Beat and Return to Profitability
Arcutis (ARQT) Q3 2025 earnings crush estimates with a surprise profit. Revenue of $99.2M beats forecasts, driving the stock up 16% on strong ZORYVE demand. 
Via Chartmill
Topics Earnings
Uncovering Potential: Arcutis Biotherapeutics's Earnings Preview
 
Via Benzinga
ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Technical Strength with High Growth Momentum
Discover ARQT stock, a top growth pick blending Minervini's strong trend template with explosive earnings and sales momentum for potential outperformance. 
Via Chartmill
Top 5 Biotech Stocks With Strong Momentum
Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies. 
Via Benzinga
3 Biotech Catalysts Present Major Opportunity
Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further. 
Via MarketBeat
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Fits the Minervini Trend Template with Strong Growth Momentum
Discover how Arcutis Biotherapeutics (ARQT) fits Mark Minervini’s Trend Template with strong technicals, high growth momentum, and fast-improving earnings—ideal for growth investors. 
Via Chartmill
Arcutis (ARQT) Q2 Revenue Soars 164%
Via The Motley Fool
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Beats Q2 2025 Revenue Estimates and Posts Narrower Loss Than Expected
Arcutis Biotherapeutics (ARQT) beats Q2 2025 revenue and EPS estimates with $81.5M in sales, driven by strong ZORYVE demand. Shares rise post-earnings. 
Via Chartmill
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis
Arcutis will present five posters at RAD 2025 featuring long-term safety and efficacy data for Zoryve cream in children with eczema. 
Via Benzinga
Analyst Expectations For Arcutis Biotherapeutics's Future
 
Via Benzinga
Would Mark Minervini consider ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) a top stock pick?
A fundamental and technical analysis of (NASDAQ:ARQT): Is ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) suited for high growth investing? 
Via Chartmill
Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews
 
Via Benzinga
Rebound Or Fakeout? The 200-Day MA Holds The Key To The Next Big Move
A discussion whether the rebound could sustain, the worst scenario and the potential target price for the S&P 500. 
Via Talk Markets
Topics Stocks Stocks / Equities
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
 
Via Benzinga
How does ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) stack up against Mark Minervini’s strategy?
A fundamental and technical analysis of (NASDAQ:ARQT): Why ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) is Poised for High Growth. 
Via Chartmill
Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?
Top performers last week: DGNX (108.29%), NEXT (25.07%), CELH (21.60%), SIG (21.08%), NFE (20.63%), MRP (16.61%), ARQT (16.35%), LCID (15.79%), CPRX (15.27%), STNE (14.20%). Are they in your... 
Via Benzinga
What's Going On With Arcutis Biotherapeutics Stock Monday?
Arcutis shares traded higher on Monday after Health Canada approved its Zoryve cream for the treatment of mild to moderate atopic dermatitis. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.